Physician profile
Michael Dewayne Roach
NPI 1740592435
$6,062.12
in general payments reported to CMS, 2019-2025
37 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $711 · 2021: $1,172 · 2022: $692 · 2023: $838 · 2024: $1,253 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,149.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.03 | 2020-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $743.21 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $742.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $567.20 | 2019-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $558.10 | 2019-2025 | Rexulti |
| Pfizer INC. | $423.65 | 2019-2025 | |
| Amgen INC. | $283.66 | 2019-2025 | Evenity, Repatha, Otezla |
| Axsome Therapeutics, INC. | $187.04 | 2023-2025 | Auvelity |
| Lundbeck LLC | $161.39 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.75 | 2020-2024 | Jardiance |
| Allergan, INC. | $133.21 | 2019-2020 | |
| Exact Sciences Corporation | $131.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $115.55 | 2020-2024 | Trintellix |
| Astellas Pharma US INC | $112.81 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $98.79 | 2019-2024 | Arexvy, Shingrix |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.